10-Q: Cyclacel Pivots to Industrial Assets Amid Going Concern

Cyclacel Pharmaceuticals, Inc. is undergoing a major strategic shift, liquidating its biopharma subsidiary and planning to acquire industrial assets, while facing a going concern warning and a new lawsuit.

Summary

• Cyclacel Pharmaceuticals, Inc. (CYCC) has initiated a significant strategic pivot, moving away from its biopharmaceutical focus to acquire and consolidate industrial assets.
• The company's wholly-owned UK subsidiary, Cyclacel Limited, which housed its clinical research programs and intellectual property, entered creditors' voluntary liquidation on January 24, 2025, leading to a $5.0 million gain on deconsolidation.
• Cyclacel will now focus solely on the plogosertib (Plogo) clinical program, having repurchased related assets for approximately $0.3 million, while its fadraciclib program is being marketed for sale by the liquidator.
• A definitive Exchange Agreement was signed with FITTERS Diversified Berhad to acquire its Malaysian subsidiary, Fitters Sdn. Bhd., for up to $1.0 million in cash and 19.99% of Cyclacel's common stock.
• Upon closing the FITTERS transaction, Cyclacel will be renamed Bio Green Med Solution, Inc. (BGMS) and expects to trade under a new Nasdaq ticker symbol, with current Cyclacel stockholders owning approximately 80.01% of the combined entity.
• The company completed a one-for-sixteen reverse stock split on May 12, 2025, and a further one-for-fifteen reverse stock split on July 7, 2025.
• Net loss for the six months ended June 30, 2025, significantly decreased to $(1.4) million from $(6.2) million in the prior year, primarily due to the deconsolidation gain.
• Cash and cash equivalents increased to $4.3 million as of June 30, 2025, from $3.1 million at December 31, 2024, driven by financing activities.
• Research and development expenses decreased by 82% to $0.9 million for the six months ended June 30, 2025, following the liquidation of the UK subsidiary and focus on Plogo.
• General and administrative expenses increased by 70% to $5.5 million for the six months ended June 30, 2025, due to one-time costs associated with two changes of control, including $1.3 million in stock compensation expense.
• A lawsuit was filed on August 6, 2025, by minority shareholder David Lazar against Cyclacel and CEO Datuk Dr. Doris Wong, alleging breach of fiduciary duty, minority shareholder oppression, and breach of contract, seeking over $12 million in damages.
• The company's auditors have issued a going concern opinion, and management anticipates current cash will only meet liquidity requirements into the fourth quarter of 2025, necessitating additional financing.

Sentiment

Score: 3

Explanation: The sentiment is low due to the severe 'going concern' warning, a complete and risky pivot in business strategy, ongoing shareholder litigation, and a history of significant share price depreciation evidenced by multiple reverse stock splits. While the reduction in net loss and liabilities is positive, it's largely due to non-recurring events and capital raises, not sustainable operational improvements in its core business.

Positives

• Net loss significantly reduced to $(1.4) million for the six months ended June 30, 2025, compared to $(6.2) million for the same period in 2024, largely due to a $5.0 million gain on subsidiary deconsolidation.
• Cash and cash equivalents increased to $4.3 million as of June 30, 2025, from $3.1 million at December 31, 2024, bolstered by financing activities.
• Total current liabilities decreased substantially to $760k as of June 30, 2025, from $6,268k at December 31, 2024, indicating improved short-term financial health.
• Stockholders' equity shifted from a deficit of $(2.2) million at December 31, 2024, to positive equity of $3.6 million at June 30, 2025.
• Regained compliance with Nasdaq's equity requirement on February 25, 2025.
• The company has streamlined its drug development focus to only the plogosertib (Plogo) clinical program, potentially reducing future R&D burn.
• Plogosertib Phase 1/2 study has treated 15 patients with no dose-limiting toxicities observed, and stable disease has been noted in pretreated patients.

Negatives

• The company reported $0 revenue for the six months ended June 30, 2025, down from $33,000 in the prior year, with no significant revenue expected from R&D activities in the foreseeable future.
• Net cash used in operating activities increased to $(4.3) million for the six months ended June 30, 2025, from $(3.6) million in the same period of 2024, indicating a higher cash burn.
• General and administrative expenses rose significantly by 70% to $5.5 million for the six months ended June 30, 2025, due to one-time costs related to changes of control.
• The company's auditors have issued a going concern opinion, and management has assessed substantial doubt about its ability to continue as a going concern for at least the next twelve months.
• Current cash and cash equivalents are only anticipated to meet liquidity requirements into the fourth quarter of 2025, necessitating additional financing.
• The company is subject to a Nasdaq Mandatory Panel Monitor for one year from February 25, 2025.
• A lawsuit has been filed by a minority shareholder against the company and its CEO, seeking over $12 million in damages, which could result in significant legal costs and financial liabilities.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, with current cash only sufficient into the fourth quarter of 2025, requiring additional financing.
• Failure to secure additional funding through equity financing or strategic transactions could force the company to curtail operations, delay development, cease operations, or file for bankruptcy.
• The proposed strategic pivot to acquiring and consolidating industrial assets is a complete change in business model, introducing new and unproven risks for the company.
• The company faces a lawsuit from a minority shareholder alleging breach of fiduciary duty, minority shareholder oppression, and breach of contract, seeking over $12 million in damages.
• The Exchange Agreement with FITTERS Diversified Berhad is subject to approval from Cyclacel stockholders and FITTERS shareholders, and may not close by the September 30, 2025, termination deadline.
• The company's common stock has undergone two significant reverse stock splits (1-for-16 and 1-for-15), which can negatively impact investor confidence and liquidity.
• The company is no longer eligible for UK research and development tax credits following the liquidation of its UK subsidiary, impacting future tax benefits.
• The company's future success is highly dependent on the successful development and commercialization of its single remaining drug candidate, plogosertib, which is still in Phase 1/2 clinical trials.
• The company's reliance on equity financing for future cash needs exposes it to market volatility and potential dilution for existing shareholders.

Future Outlook

The company anticipates seeing growth in revenues during the fourth quarter of 2025 if the Exchange Agreement with FITTERS Diversified Berhad is successfully completed. Overall research and development expenses for the year ended December 31, 2025, are expected to decrease significantly as the company focuses solely on the plogosertib program. General and administrative expenditures for 2025 are projected to be higher than 2024 due to one-time costs, and overall expenditures are expected to increase significantly in Q4 2025 if the FITTERS transaction closes. The company is actively pursuing financing to maintain operations while evaluating potential business opportunities, including mergers, acquisitions, or share exchanges, and aims to acquire and consolidate complementary industrial assets to generate scalable enterprises.

Management Comments

• Management is required at each reporting period to evaluate whether there are conditions or events that raise substantial doubt about an entity's ability to continue as a going concern within one year.
• We are currently investigating ways to raise additional capital through private equity financing or by entering into a strategic transaction.
• In the event that we are not able to secure funding, we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.
• Our Board of Directors has begun to analyze strategic alternatives available to the Company to continue as a going concern, including raising additional debt or equity financing or consummating a merger or acquisition with a partner that may involve a change in our business plan.
• We believe we would be an attractive candidate for such a business combination due to the perceived benefits of being a publicly listed company, thereby providing a transaction partner access to the public marketplace to raise capital.
• We plan to acquire and consolidate complimentary industrial assets, typically core manufacturers and suppliers of specific bulk commodity minerals and chemicals.
• We believe that smaller, legacy-owned industrial companies will benefit from economies of scale and professional asset allocation.
• The company believes the claims in the David Lazar lawsuit to be meritless and intends to vigorously defend the lawsuit.

Industry Context

Cyclacel is undergoing a radical transformation, exiting the highly competitive and capital-intensive biopharmaceutical industry, where it struggled to generate revenue and faced significant R&D costs. The liquidation of its UK subsidiary and the divestment of fadraciclib signal a complete departure from its original mission. The proposed merger with FITTERS Diversified Berhad and the strategic shift to acquiring industrial assets (minerals and chemicals) represents a pivot into a completely different sector. This move is driven by the company's inability to secure sufficient funding for its drug development pipeline and its 'going concern' status, aiming to leverage its public listing for a new business model focused on industrial consolidation. This is a highly unusual and risky maneuver, effectively turning the company into a shell for a new, unrelated venture.

Comparison to Industry Standards

• The company's shift from biopharmaceuticals to industrial asset consolidation makes direct comparison to its former biopharma peers (e.g., other clinical-stage oncology companies) largely irrelevant for future performance.
• No specific comparable companies, projects, or results within the industrial asset consolidation sector are mentioned in the filing to assess the new strategy against industry benchmarks.
• The company's historical lack of revenue and significant accumulated deficit are below industry standards for successful biopharmaceutical companies, which typically require substantial capital and successful clinical outcomes to generate revenue.
• The repeated reverse stock splits are indicative of significant share price underperformance, which is generally worse than industry standards for stable, growing companies.

Management Changes

Corporate Governance

Legal Proceedings

• On August 6, 2025, David Lazar, a minority shareholder, filed a complaint in the United States District Court Southern District of New York against Cyclacel Pharmaceuticals, Inc. and Datuk Dr. Doris Wong Sing Ee (CEO and majority shareholder).
• The complaint alleges three causes of action: (1) breach of fiduciary duty (against Company and Datuk Dr. Wong); (2) minority shareholder oppression (against Datuk Dr. Wong); and (3) breach of contract (against Datuk Dr. Wong).
• The complaint requests damages of $11,882,683.45 for the first and second causes of action, and $629,501.36 for the third cause of action, plus pre-judgment and post-judgment interest, and attorneys' fees.
• The company believes the claims are meritless and intends to vigorously defend the lawsuit.

Related Party Transactions

• On January 2, 2025, the company entered into a securities purchase agreement with David E. Lazar for $3.1 million in Series C and D Convertible Preferred Stock.
• On February 11, 2025, David E. Lazar (then interim CEO and Secretary) entered into a securities purchase agreement with Datuk Dr. Doris Wong Sing Ee (who became CEO and majority shareholder) to sell his Series C and D Preferred Stock.
• In a December 2023 insider private placement, Spiro Rombotis (CEO) and Paul McBarron (EVP-Finance, CFO, COO) purchased common stock and warrants.

Stakeholder Impact

• **Shareholders**: Face significant dilution from past and potential future capital raises, and two recent reverse stock splits. The strategic pivot introduces high uncertainty and a complete change in investment thesis. A minority shareholder lawsuit against the company and CEO adds legal and financial risk.
• **Employees**: The liquidation of the UK subsidiary and focus solely on the Plogo program likely resulted in job losses related to the fadraciclib program. The new strategic direction may lead to a different employee skill set requirement.
• **Creditors**: Proceeds from recent capital raises were used to settle outstanding liabilities, which is positive for creditors. However, the 'going concern' warning indicates ongoing risk.
• **Customers/Suppliers**: The biopharma customer/supplier base will be significantly impacted by the strategic pivot. The new industrial asset consolidation strategy will involve a completely different set of customers and suppliers, with unknown relationships and market position.
• **Regulatory Bodies**: Nasdaq compliance has been regained, but the company is under a one-year monitor, indicating continued oversight.

Next Steps

• Seek stockholder approval for the Exchange Agreement with FITTERS Diversified Berhad.
• Complete the closing of the Exchange Agreement with FITTERS Diversified Berhad by September 30, 2025, to avoid termination.
• Rename the company to Bio Green Med Solution, Inc. and obtain a new Nasdaq ticker symbol (BGMS) upon closing the FITTERS transaction.
• Continue development of the plogosertib (Plogo) clinical program, including developing a new oral formulation with improved bioavailability.
• Actively pursue additional financing through equity offerings, debt financings, or strategic collaborations to address the going concern risk.
• Defend against the lawsuit filed by David Lazar, which alleges breach of fiduciary duty, minority shareholder oppression, and breach of contract.
• Identify and evaluate new business opportunities, particularly in the industrial asset consolidation sector, as part of the new strategic direction.
• Appoint at least one officer or director from FITTERS or Fitters Sub to Cyclacel's board upon closing the Exchange Agreement.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, with current cash only projected to last into Q4 2025. The complete pivot from biopharmaceuticals to industrial asset consolidation is a highly speculative and unproven strategy for this entity, effectively transforming it into a new, high-risk venture. This is compounded by a significant lawsuit from a minority shareholder and a history of severe share price depreciation leading to multiple reverse stock splits. For a seasoned investor, the extreme uncertainty, operational risks, and legal challenges outweigh any potential upside from the new strategy, making a 'sell' recommendation prudent to avoid further capital erosion.

Keywords

Biopharma, Strategic Alternatives, Going Concern, SEC Filing, 10-Q, Plogesertib, Clinical Trials, Reverse Stock Split, Nasdaq Compliance, Industrial Assets, Merger, Acquisition, Capital Raise, Lawsuit, Shareholder Oppression, Biotechnology, Pharmaceuticals